Buradasınız

Anasayfa » Content

IL-lp, IL-6, TNF-a, CRP ve ESH Hemodiyaliz Hastalarında Hepatit B Aşısına Antikor Yanıtsızlığının Göstergesi Olabilir mi?

Can IL-1p, IL-6, TNF-a, CRP and ESR Be the Marker of Unresponsiveness of Antibody Against Hepatitis B Vaccine in Hemodialysis Patients?

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2005

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Aim: The hepatitis B infection is a subject that still keeps its significance for hemodialysis staff members and hemodialysis patients at present. In this study, our aim was to evaluate whether the infections occurring during the hepatitis B vaccination programme have some negative effects on antibody response and also to exa¬ mine the increased proinflammatory cytokins, interleukin-1p (IL- 1P), interleukin-6 (IL-6), tumor necrosis factor-a(TNF-a), C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) as inflam¬ mation markers in the hemodialysis patients. Materials and Methods: The patients who have hemodialysis adequacy, who are on rHuEPO therapy, whose hepatitis markers were HBsAg (-), antiHBs (-), antiHBcIgG (-) and anti HCV (+) or (-)and the patients who had sufficient antibody response at the begi-ning of the hemodialysis but then the antibody titers fell below the 10 mIU/mL were enrolled in the study in Hemodialysis Center of Dicle University Faculty of Medicine. The patients were divided in¬to two groups according to vaccination procedures. Group A: The 40 |ig hepatitis B vaccine was injected intramuscularly into the left shoulder of patients who were HBsAg (-) and antiHBs (-) at months 0, 1, 2 and 6. Group B: The 40 |ig booster dose of hepatitis B vaccine was injected intramuscularly into the left shoulder of the patients who had sufficient antibody response at the beginning of the hemodialysis but then the antibody titers fell below 10 mIU/mL. Then, the Group A was divided into two subgroups as Group A1 and Group A2 according to antibody response. Recombinant hepatitis B vaccine (Hepavax - Gene-inj (R) recombinant 20 |ig/ml, Gre¬en Cross Vaccine Corp., Korea) was administered. Results: Twenty-eight patients completed the study (Group A: n=21, mean age 41±11 years, mean period of HD time 15.1±14.7 months, mean URR 68.7±7.4, mean Kt/V 1.45±0.23; Group B: n=7, mean age 55±16 years, mean period of HD time 22.2±26.8 months, mean URR 68.2±8.1, mean Kt/V 1.41±0.34). The positive antibody rate was 71.4% and the negative antibody response was 28.6% in group A. The positive antibody response rate was 100% in group B. There were not significant differences between the parameters of demographics, hematologic characteristics and nutritional status of the groups (p>0.05). The inflammation markers were similar in both groups except TNF-a because TNF-a was higher in group B. It was established that the majority of infections occured in group A1 during the study. Conclusions: The patients whose HBV serologic markers were negative should be vaccinated with recommended vaccination schedule, while starting the HD therapy. Also the booster dose should be applied to the vaccinated patients whose antibody titers fell below the 10 mIU/mL. The acute infections that occured during this period and inflammations did not negatively affect the antibody response. It was considered that the acute phase markers did not reflect the negative antibody response.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Hepatit B virüs (HBV) infeksiyonu hemodiyaliz (HD) ünitesi çalışanları ve hastaları için günümüzde hâlâ önemini koruyan bir sorundur. Bu çalışmada amacımız, HD hastalarında hepatit B aşı programı süresince gelişen infeksiyonların antikor yanıtı üzerine olumsuz etkisinin olup olmadığını ve dolayısıyla artan proinflamatuar sitokinler interlökin-1p (IL-1P), interlökin-6 (IL-6), tümör nekrozis faktör-a (TNF-a), C-reaktif protein (CRP) ve eritrosit sedimentasyon hızı (ESH) gibi inflamasyon göstergelerini de¬ ğerlendirmektir. Hastalar ve Yöntem: Dicle Üniversitesi Tıp Fakültesi HD Merkezi'nde, HD yeterliliği olan, rHuEPO tedavisi alan, HBsAg (-), antiHBs (-), antiHBcIgG (-) ve antiHCV (+) veya (-) olan hastalar ile önceden aşılanmış, antikor titresi daha sonra 10 mIU/mL'nin altına düşmüş hastalar çalışmaya alındı. Hastalar aşılanma durumuna göre iki gruba ayrıldı: Grup A'daki HBsAg (-) ve antiHBs (-) olan hastalara 0, 1, 2 ve 6. aylarda olmak üzere 40 |jg aşı (Hepavax - Gene-inj (R) rekombinant 20 |jg/ml, Green Cross Vaccine Corp, Kore) uygulandı; Grup B'deki, daha önce aşılanıp, antikor titresi 10 mIU/mL'nin altına düşmüş olan hastalara ise 40 |jg rapel doz aşı intramüsküler uygulandı. Antikor titresi 10 mIU/ml'nin üzerinde olanlar, antikor yanıtı pozitif kabul edildi. Grup A, daha sonra antikor yanıtına göre iki altgruba (Grup A1 ve Grup A2) ayrıldı.Bulgular: Çalışmayı 28 hasta tamamladı (Grup A: n=21, yaş ortalaması 41±11 yıl, ortalama HD süresi 15.1±14.7 ay, ortalama URR 68.7±7.4, ortalama Kt/V 1.45± 0.23; Grup B: n=7, ortalama yaş 55±16 yıl, ortalama HD süresi 22.2±26.8 ay, ortalama URR 68.2±8.1, ortalama Kt/V 1.4±0.34). Grup A'da hepatit B aşılamasına karşı pozitif antikor yanıtı %71.4, negatif antikor yanıtı ise %28.6 oranında gerçekleşti. Rapel doz uygulanan Grup B'de ise tüm olgularda (%100) pozitif antikor yanıtı gerçekleşti. Aşı programının başında ve sonunda Grup A'da pozitif antikor yanıtı oluşturan (15/21) hastalarla (Grup A1), antikor yanıtı negatif olan (6/21) hastaların (Grup A2) ve rapel doz aşı grubunun demografik ve hematolojik özellikleriyle beslenme duru¬ mu parametrelerinde anlamlı bir farklılık saptanmadı (p>0.05). Grup A1'de TNF-a yüksekliğinin dışında diğer inflamasyon göstergeleri, Grup A2 ile benzer iken, Grup B'de daha yüksek saptandı. Çalışma sürecince en sık infeksiyonun Grup A1'de geliştiği saptandı. Sonuç: HD tedavisine başlarken HBV serolojik göstergesi negatif olan hastalar önerilen aşı şemasıyla aşılanmalı, aşılanmış hastalardan antiHBs antikor titresi 10 mIU/mL'nin altına düşmüş olanlara da rapel doz aşı uygulanmalıdır. Bu süre zarfında gelişen akut infeksiyonların ve inflamasyonun antikor yanıtını negatif yönde et¬ kilemediği ve akut faz yanıt göstergelerinin, negatif antikor yanıtı¬ nın bir göstergesi olamayacağı düşünülmektedir.
FULL TEXT (PDF): 
PDF icon pdf_tndt_547.pdf
  • 4
188-194
  • Turkish

REFERENCES

References: 

1. Neto MC, Draibe SA, Silva AEB, et al. Incidence of and risk factors for hepatitis B virus and hepatitis C virus infection among haemodialysis and CAPD patients: evidence for environmental transmission. Nephrol Dial Transplant 1995; 10: 240-246.
2. Josselson J, Kyser BA, Weir MR, Sadler JH. Hepatitis B sur¬face antigenemia in a chronic hemodialysis program: lack of influence on morbidity and mortality. Am J Kidney Dis 1987;
9: 456-461
3. Jadoul M, Van Y Persele de Strihou C. Viral hepatitis in di¬alysis patients. Trends Exp Clin Med 1993; 4: 36-40.
4. Centers for Disease Control and Prevention. Consultant Me¬eting to Update Recommendations for the Prevention and Control of Bloodborne and Other Infections Among Chronic Hemodialysis Patients. Atlanta, Georgia 1999 MMWR 2001; 50(RR05):1-43
5. Köhler H. Hepatitis B immunization in dialysis patients - is it worthwhile? Nephrol Dial Transplant 1994; 9: 1719-1720
6. Raine AEG, Margreiter R, Brunner FP, et al. Report on mana¬gement of renal failure in Europe XXII,1991. Nephrol Dial
Official Journal of the Turkish Society of Nephrology/ Türk Nefroloji Diyaliz ve Transplantasyon Dergisi
193
Can IL-1 fi, IL-6, TNF- a CRP and ESR Be the Marker of Unresponsiveness of Antibody Against Hepatitis B Vaccine?
Transplant 1992; 7(suppl 2):7-14
7.
Hemodiyali
z hastalarında hepatit serolojisi. Türkiye 2002 Yılı Ulusal Hemodiyaliz, Transplantasyon ve Nefroloji Kayıt Sistemi Raporu. Art Ofset, İstanbul, 2003 Sayfa:14.
8.
Mıstı
k R, Balık İ. Türkiye'de viral hepatitlerin epidemiyolojik analizi. Viral Hepatitle Savaşım Derneği, Karakter Color A.Ş.
Ankara 2003, p 15
9.
Tekel
i E. Hepatit B aşısı ve hepatit B'den korunma. Viral hepatit 2003. Viral Hepatitle Savaşım Derneği Yayını. Ankara
2003,179-182
10. Anandh U, Thomas PP, Shastry JC, Jacob CK. A randomised controlled trial of intradermal hepatitis B vaccination and augmentation of response with erythropoietin. J Assoc Physicians India 2000; 48(11):1061-3.
11. Peces R, de la Torre M, Alcazar R, Urra JM. Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients. Am J Kidney Dis 1997;29(2):239-45.
12. Charest AF, Grand'Maison A, McDougall J, Goldstein MB. Evolution of naturally acquired hepatitis B immunity in the long-term hemodialysis population. Am J Kidney Dis 2003; 42(6):1193-9.
13. NKF/DOQI. Guidelines for hemodialysis adequacy. II. He-modialysis dose guideline 4: minimum delivered dose of he-modialysis (adults evidence, children opinion) 29/02/2004
14. Elwell RJ, Neumann M, Bailie GR. Factors associated with long-term antibody production induced by hepatitis B vacci¬ne in patients undergoing hemodialysis: a retrospective co¬hort study. Pharmacotherapy 2003;23(12):1558-63.
15. Kovacic V, Sain M, Vukman V. Efficient haemodialysis imp¬roves the response to hepatitis B virus vaccination. Intervi-
rology 2002;45(3):172-6
16. Hassan K, Shternberg L, Alhaj M, Giron R, Reshef R, Barak M,
Kristal B. The effect of erythropoietin therapy and hemoglo¬bin levels on the immune response to Engerix-B vaccination in chronic kidney disease. Ren Fail 2003;25(3):471-8.
17. Sennesael JJ, Van der Niepen P, Verbeelen DL. Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients. Kidney Int 1991l;40(1):121-8.
18. Fernandez E, Betriu MA, Gomez R, Montoliu J. Response to the hepatitis B virus vaccine in haemodialysis patients: inf¬luence of malnutrition and its importance as a risk factor for morbidity and mortality. Nephrol Dial Transplant 1996; 11(8):1559-63.
19. Vlassopoulos D. Recombinant hepatitis B vaccination in renal failure patients. Curr Pharm Biotechnol 2003;4(2):141-51.
20. Girndt M, Kohler H, Schiedhelm-Weick E, Schlaak JF, Meyer
zum Buschenfelde KH, Fleischer B. Production of inter-leukin-6, tumor necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int 1995;47(2):559-65.
21. Yılmaz E, Kara IH, Sarı Y. Are Polysulfone Dialysers Stimu¬lating Cytokines in Hemodialysed Patients With Hepatitis C? Dialysis & Transplant 2001; 5: 288-298.
22. Kimmel PL, Phillips TM, Simmens SJ, et al. Immunologic function and survival in hemodialysis patients. Kidney Inter¬national 1998; 54(1):236
23. Bel'eed K, Wright M, Eadington D, Farr M, Sellars L. Vac¬cination against hepatitis B infection in patients with end
stage renal disease. Postgrad Med J 2002;78(923):538-40.
24. Bryl E, Mysliwska J, Debska-Slizien A, et al. The influence of recombinant human erythropoietin on tumor necrosis factor alpha and interleukin-10 production by whole blood cell cul¬tures in hemodialysis patients. Artif Organs 1998;22(3): 177-81.

Thank you for copying data from http://www.arastirmax.com